Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We also see meaningful revenue contribution stemming from the potential for a triple combination therapy in Europe, additional milestone payments from our network of partners, additional ex-U.S |
| opportunities and continued growth stemming from further advancement of our preclinical pipeline |
| Further development of these assets could help us expand beyond lipids and enter into new markets with significant unmet need, increase our addressable market, extend our product life cycle and open the door to additional partnering opportunities as well as help us achieve long-term sustainable growth |
| We again delivered another quarter of continued growth in retail prescription equivalents, which increased 44% year-over-year and 8% quarter-over-quarter and was accomplished even with our current label and promotional footprint before recently ramping up our in-house sales force |
| So, we feel very confident in that regard |
| and in our global territories is a testament to the strength of our clinical data, the unmet need in the market and our teams and partners' abilities to execute |
| We ended the year on a strong note, which really emphasizes the point that outcomes data matters, and we're excited for that data to be incorporated into our new label next month and for what it means for patient access and our ability to actively promote the data for the first time |
| We delivered another strong quarter that positions us for continued success in the long-term and significantly transforms our capital position and investment profile |
| Prescription growth continued at a strong pace, and we're proud of the momentum that we sustained through the end of the year |
| We further strengthened our balance sheet with additional capital, emphasizing our strong cash position and bringing in several new long-term biotech investors |
| And with that said, we also have a steady stream of catalysts for our long-term continued growth |
| We had a very strong quarter, and that quarter is really going to and has created strong momentum as we enter into the first quarter of 2024 |
| As Sheldon already mentioned, we posted strong fourth quarter results and ended the year with continued momentum, including in new-to-brand prescriptions |
| Importantly, we believe the closure of this matter significantly strengthens our investment profile, reduces costs associated with the litigation and is an excellent outcome for both parties |
| It provides for a significant near-term cash payments, inventory and gross margin savings and potentially extend our European product life cycle while generating additional potential royalty streams in the DF territories |
| We are pleased to report another strong quarter as well as key material events in January that we believe put our company on solid footing and further position us for continued long-term success |
| Combining our year-end cash balance with the $100 million settlement payment received in January and proceeds from our recent offering, we significantly strengthened our liquidity position, which enables us to invest in initiatives that support the long-term success of Esperion |
| With the litigation now resolved and the infusion of additional cash, we are poised for significant growth in 2024 |
| These are significant changes to our current label, supported by our robust CLEAR Outcomes data and are expected to drive substantial future growth |
| I'm pleased to share that reviews of our pending applications with the FDA and EMA are progressing extremely well, and these positive discussions remain in line with our strategic goals |
| Longer term, the optimization of our balance sheet and partnership-related cost savings should enable us to continue to enhance our capital position over time |
| Furthermore, our partners will continue launching our products in even more new territories under regular cadence, creating additional revenue streams and bolstering our growing global franchise |
| I'm happy to say we've made great progress with the payers |
| We believe our recent achievements and changes we've implemented set us up for long-term sustained growth |
| We're also pleased to announce that ICER, the Institute for Clinical and Economic Review, just determined NEXLIZET as a cost-effective therapy, which adds support for its value proposition to payers |
| So, we feel very confident about our payer strategy and the interactions that we have had with them |
| We are well poised for the new label, and we're very excited, and those discussions have been continuing since last year's ACC to current day |
| In summary, I'm excited for what I believe lies in store for us both now and in the future, and our path has never been clear or brighter |
| We've had some very positive interactions with the FDA |
| You'll see that this steady stream of catalysts begin to form a road map for long-term value growth |
| Statement |
|---|
| R&D expense was $17.7 million, a decrease of 46% year-over-year, reflecting substantially lower costs following the closeout of our CLEAR Outcomes trial |
| Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business |
| But as you know, that change that we saw removed the maximally tolerated requirement, but it still kept statins and full payer changes didn't happen with regards to that removal |
Please consider a small donation if you think this website provides you with relevant information